# Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG

> **NCT00899847** · PHASE2 · COMPLETED · sponsor: **Stanford University** · enrollment: 9 (actual)

## Conditions studied

- Transplantation, Homologous
- Transplantation, Autologous
- Multiple Myeloma
- Blood and Marrow Transplant (BMT)

## Interventions

- **PROCEDURE:** Autologous peripheral blood stem cells (auto-PBSC) transplantation
- **PROCEDURE:** Allogeneic peripheral blood stem cells (allo-PBSC) transplantation
- **DRUG:** Filgrastim
- **DRUG:** Cyclophosphamide
- **DRUG:** Melphalan
- **DRUG:** Cyclosporine
- **RADIATION:** Total lymphoid irradiation
- **BIOLOGICAL:** Rabbit anti-thymocyte globulin
- **DRUG:** Mycophenolate Mofetil 250mg
- **DRUG:** Solumedrol
- **DRUG:** Diphenhydramine
- **DRUG:** Acetaminophen
- **DRUG:** Hydrocortisone

## Key facts

- **NCT ID:** NCT00899847
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2014-04
- **Final completion:** 2014-12
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2017-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00899847

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00899847, "Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00899847. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*